SNP•its was launched in September 2014 to provide interpretation and perspectives on clinical pharmacogenomics research. Our study summaries and interpretations are written by clinical pharmacists for other pharmacists, health care professionals, and researchers. We use an evidence-based approach to answer questions about the implications of pharmacogenomics research for patient care: What do clinical guidelines say about a specific drug–gene pair reviewed in a recent study? What is the quality of the evidence supporting genotype-guided therapy? How are pharmacogenomic test results interpreted to guide drug therapy changes? To learn more, browse our SNP•its Study Summaries or Literature Digests by Topic.
Our goal is to serve as a clinician-focused platform to educate pharmacists and other health care professionals about interpreting and applying relevant pharmacogenomics research to practice. By doing this, we strive to increase awareness and understanding of the clinical applications of pharmacogenomics, and the essential roles that pharmacists and other health care professionals play in applying this information.
The SNP•its editorial team monitors leading medicine, pharmacy, pharmacogenomics, and genomic medicine journals on a daily basis. We evaluate each article for clinical relevance and scientific validity and integrate research findings into the best available pharmacogenomic evidence to develop evidence-based clinical recommendations. In this way, SNP•its content is driven by the best available and most current pharmacogenomic evidence.
SNP•its Study Summaries
SNP•its relies on peer-reviewed literature and an evidence-based approach to support clinical recommendations in study summaries that meet clinical relevance criteria (summarized below). Writers and editors collaborate with pharmacogenomics researchers and clinicians for feedback and interpretation of articles.
To develop recommendations in SNP•its study summaries, we use clinical resources available through PharmGKB and other evidence-based sources to connect emerging research findings on specific gene-drug pairs with a) existing evidence-based CPIC or other guidelines that provide recommendations on using genetic tests to optimize drug therapy; b) the associated level of evidence for each variant-drug association; c) pharmacogenomics information included in Food and Drug Administration labeling.; and d) clinical and practice-based evidence guiding treatment of the underlying condition.
As with any area of emerging sciences, pharmacogenomics trials and research findings have varied levels of readiness for application to clinical practice or implementation. Our goal is to focus on research findings most readily applicable and relevant to practicing clinicians. As such, we employ the following basic criteria when evaluating literature for inclusion in SNP•its:
- Investigations and/or reviews of clinically relevant drug-gene pairs, where clinical relevance is defined as a gene-drug pair that a) is classified as having level 1A or 1B evidence according to the Pharmacogenomics KnowledgeBase (PharmGKB); b) is associated with a published or in-progress clinical guideline (e.g., Clinical Pharmacogenetics Implementation Consortium [CPIC]); or c) otherwise has a level of evidence sufficient to support investigation of patient-oriented outcomes with genotype-guided therapy. Supporting evidence is categorized according to the PharmGKB Clinical Annotation Levels of Evidence and/or evidence level definitions for CPIC gene-drug pairs, as appropriate.
- Research, commentary, or other notable publications that investigate or describe strategies for implementing pharmacogenomics and/or genomic medicine clinically (e.g., clinical decision support, provider education and training, cost-effectiveness of genomic testing).
- Investigations and/or reviews of patient or health care professional attitudes, knowledge, and beliefs surrounding clinical implementation of pharmacogenomics and/or genomic medicine and factors that may influence these.
SNP•its engages experienced clinicians and researchers to provide feedback on interpreted summary articles prior to publication. We are currently seeking peer reviewers with research and/or practice experience in clinical pharmacogenomics or genomic medicine. If you are interested in serving on the SNP•its Peer Review Panel, please send your curriculum vitae and a brief summary of your research and practice areas to the SNP•its editor, Kristin Weitzel at email@example.com.
Submitting an Article
If you are a pharmacist, pharmacogenomics researcher or trainee, or other health care professional interested in clinical implementation of pharmacogenomics who would like to submit a study summary for publication in SNP•its, please contact Kristin Weitzel at firstname.lastname@example.org for editorial and article submission guidelines.